V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330002173 | 330001219 | 1.69 | null | null | 2017-12-07 | 2017-12-11 | EW EuroEwing 2012 Arm B VDC | N | 0 | 330008157 | TRIAL |
| 210026690 | 210011237 | 1.72 | 91.9 | Curative (C) | 2017-08-27 | 2017-10-09 | Trial Unspecified | 02 | 0 | 210028874 | TRIAL |
| 330006507 | 330003280 | 0.8 | 16.6 | Neo-adjuvant (N) | 2017-11-11 | 2017-11-24 | NB HRNBL-1 COJEC Ind COURSE C | null | 0 | 330002231 | NOT MATCHED |
| 40049349 | 40030798 | -1 | null | Not known (9) | 2017-06-07 | 2017-06-10 | VAC | 2 | 0 | 40150635 | CAPECITABINE + RT |
| 40049431 | 40030852 | null | 71 | Not known (9) | 2016-11-30 | 2016-12-19 | VAC | N | 0 | 40161489 | CISPLATIN |
| 160016593 | 160009066 | 1.66 | null | Palliative (P) | 2016-07-22 | 2016-07-22 | FCR Oral - Cycle 1 | 2 | 0 | 160025221 | FCR |
| 160018831 | 160010240 | 1.77 | 95 | Curative (C) | 2014-12-30 | 2015-01-03 | MATRIX (lymphoma) | 0 | 0 | 160028708 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 160019583 | 160010651 | 1.76 | 88.7 | null | null | 2017-04-12 | Capecitabine | null | 0 | 160024812 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 160020185 | 160011178 | 1.49 | 94.25 | Curative (C) | 2014-11-06 | 2015-04-09 | CHOP R - 14 days | N | 0 | 160001566 | CHOP R |
| 160026842 | 160017252 | 1.75 | 73 | Curative (C) | 2015-04-14 | 2015-04-25 | ICE-R | N | 0 | 160024007 | ICE-R |
| 210005698 | 210001982 | 1.6 | 68.6 | Palliative (P) | null | 2014-11-28 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | 0 | 210017546 | FCR |
| 210034485 | 210008330 | null | 57.7 | Curative (C) | 2014-11-19 | 2014-11-19 | UKALL14- Maintenance | Y | 0 | 210015220 | UKALL2014 |
| 210007157 | 210002439 | null | 89 | Palliative (P) | 2015-03-04 | 2015-04-05 | FCR | N | 0 | 210022063 | FCR |
| 330006317 | 330003113 | 1.88 | 23.8 | Neo-adjuvant (N) | 2014-10-07 | 2014-10-07 | NB HRNBL-1 ch14.18/CHO(trial) +IL-2 | null | 0 | 330000924 | NOT MATCHED |
| 210008567 | 210002776 | null | 94.6 | Curative (C) | null | 2016-10-05 | CNS Medbl HR Cisplatin/Vinc/Cyclophos/GCSF | N | 0 | 210026724 | NOT MATCHED |
| 210008710 | 210002805 | 0 | null | Curative (C) | 2013-06-01 | 2013-07-14 | CNS PNET III Vinc, Cyclo, Etoposide | 1 | 0 | 210027215 | NOT MATCHED |
| 210008944 | 210002869 | null | null | Curative (C) | 2018-06-29 | 2018-06-30 | BMT | N | 0 | 210027964 | NOT MATCHED |
| 210009207 | 210034043 | 1.69 | 15.8 | Curative (C) | 2015-05-12 | 2015-05-26 | null | N | 0 | 210028775 | NOT MATCHED |
| 210009376 | 210034049 | 1 | null | Curative (C) | 2017-11-18 | 2017-12-01 | ALL UKALL2011 Maintenance B1 | 1 | 0 | 210029272 | UKALL 2011 |
| 210009482 | 210035421 | null | 17 | Curative (C) | 2013-09-22 | 2013-09-23 | ALL UKALL2011 TRIAL | Y | 0 | 210029599 | UKALL 2011 |
| 210005775 | 210002006 | 1.66 | 88.4 | Disease modification (D) | 2015-08-02 | 2015-08-14 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | 0 | 210017812 | FCR |
| 210009521 | 210029026 | 0 | null | Curative (C) | 2014-06-27 | 2014-07-01 | ALL UKALL 2011 Trial | 01 | 0 | 210029731 | UKALL 2011 |
| 210009697 | 210029039 | null | null | Curative (C) | 2015-02-20 | 2015-02-24 | ALL UKALL2011 Ind A Sht Dex (PAsp) | Y | 0 | 210030262 | UKALL 2011 |
| 210009898 | 210037964 | 1.73 | 83.2 | Curative (C) | 2017-02-13 | 2017-02-14 | UKALL14- Ph 1 Induction | 02 | 0 | 210030925 | UKALL2014 |
| 210010027 | 210037094 | 1.68 | 72 | Palliative (P) | 2017-10-20 | 2017-10-20 | Rituximab | 02 | 0 | 210031316 | RITUXIMAB |
| 210010346 | 210024309 | 1.68 | 91.4 | Curative (C) | 2017-02-08 | 2017-02-08 | UKALL14- Ph 1 Induction | 01 | 0 | 210032357 | UKALL2014 |
| 210012409 | 210003739 | 0 | 0 | Palliative (P) | 2018-08-18 | 2018-08-19 | RIALTO TRIAL | 01 | 0 | 210039106 | RIALTO TRIAL |
| 210012533 | 210003776 | null | null | null | 2014-02-15 | 2014-02-17 | CNS LGG 2004 03 vinc weekly+ carbo | 1 | 0 | 210039491 | CARBOPLATIN + VINCRISTINE |
| 210013198 | 210003990 | 0 | 69 | Palliative (P) | null | 2016-05-12 | Abiraterone | null | 0 | 210041621 | LOMUSTINE + PROCARBAZINE + VINCRISTINE |
| 210018653 | 210010059 | 1.89 | 91.2 | Curative (C) | 2016-10-07 | 2016-10-07 | UKALL14- Ph 1 Induction | Y | 0 | 210020885 | UKALL2014 |
| 210019012 | 210010443 | 0 | 16.3 | Curative (C) | 2014-10-07 | 2014-10-11 | CYTARABINE + MERCAPTOPURINE + METHOTREXATE + PEGASPARAGINASE + VINCRISTINE | 02 | 0 | 210022960 | NOT MATCHED |
| 210020059 | 210011487 | 1.67 | 13.9 | Curative (C) | 2014-11-08 | 2014-11-19 | ESPHALL TRIAL | Y | 0 | 210029795 | TRIAL |
| 210020072 | 210011500 | 1.72 | 96.3 | Palliative (P) | 2014-11-28 | 2014-12-28 | Temozolomide + RT | N | 0 | 210029842 | TEMOZOLOMIDE + RT |
| 210020078 | 210027434 | 0.98 | 15.9 | Adjuvant (A) | 2015-03-06 | 2015-04-25 | Trial Unspecified | N | 0 | 210029868 | TRIAL |
| 210020131 | 210011566 | null | 64.9 | Curative (C) | 2013-07-13 | 2013-08-04 | Temozolomide + RT | null | 0 | 210030138 | TEMOZOLOMIDE + RT |
| 210024672 | 210007479 | 1.7 | null | Curative (C) | 2017-06-20 | 2017-06-28 | ALL UKALL2011 Maintenance C2 | 01 | 0 | 210013321 | UKALL2011 |
| 210025966 | 210010189 | 1.66 | 6.6 | Disease modification (D) | 2017-08-11 | 2017-11-23 | CNS Headstart II Myeloablation | N | 0 | 210021334 | NOT MATCHED |
| 210026447 | 210010785 | 1.75 | null | Adjuvant (A) | 2013-09-08 | 2013-09-30 | Temozolomide + RT | N | 0 | 210026935 | TEMOZOLOMIDE + RT |
| 210009485 | 210035421 | null | 42.4 | Curative (C) | 2014-08-02 | 2014-08-10 | CNS Ependy II VEC | N | 0 | 210029599 | NOT MATCHED |
| 210028037 | 210013683 | 0 | null | Curative (C) | 2018-11-11 | 2018-11-16 | IVE-R | N | 0 | 210008519 | TAMIGA TRIAL |
| 210030565 | 210010697 | null | 64.5 | Curative (C) | null | 2016-02-19 | Temozolomide + RT | N | 0 | 210025775 | TEMOZOLOMIDE + RT |
| 220004081 | 220015741 | null | 45.3 | Curative (C) | null | 2016-02-24 | Hydroxycarbamide | null | 0 | 220025348 | HYDROXYCARBAMIDE |
| 210035732 | 210007998 | 1.83 | 89.7 | Palliative (P) | 2018-02-23 | 2018-04-04 | UKALL14- Ph 2 Induction | Y | 0 | 210014497 | UKALL2014 |
| 210035813 | 210008552 | 1.05 | 16.75 | Curative (C) | 2017-09-03 | 2017-09-03 | CNS PNET 5 Medbl L/StRsk Mnt B | 99 | 0 | 210015695 | NOT MATCHED |
| 210035884 | 210008941 | 1.54 | 0 | Curative (C) | 2017-12-11 | 2017-12-12 | Trial Unspecified | Y | 0 | 210017005 | TRIAL |
| 210035889 | 210008958 | 1.73 | 75.4 | Curative (C) | null | 2017-11-07 | Trial Unspecified | Y | 0 | 210017073 | TRIAL |
| 210038064 | 210007360 | 1.57 | 48.5 | Curative (C) | 2018-03-09 | 2018-08-28 | CNS HGG HERBY Bevacizumab | Y | 0 | 210013090 | TRIAL |
| 220003285 | 220001417 | 1.72 | null | Curative (C) | 2016-02-19 | 2016-03-11 | Azacitidine | N | 0 | 220023705 | AZACITIDINE |
| 220003753 | 220001568 | 1.7 | 62 | Disease modification (D) | 2013-07-17 | 2013-07-24 | Azacitidine | N | 0 | 220024665 | AZACITIDINE |
| 210008535 | 210002765 | null | 5.3 | Curative (C) | null | 2013-05-14 | ALL UKALL2011 Maintenance C4 | 1 | 0 | 210026606 | NOT MATCHED |